https://doi.org/10.4081/aiua.2024.12582

Efficacy of palmitoylethanolamide, epilobium and calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III

Vol. 96 No. 2 (2024)
Submitted: May 12, 2024
Accepted: June 7, 2024
Published: June 27, 2024
Chronic prostatitis, chronic pelvic pain syndrome, palmitoylethanolamide, epilobium, calendula
Abstract Views: 60
PDF: 17
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Giuseppe Morgia
giuseppe.morgia@unict.it
Unit of Urology, Mediterranean Oncological Institute (IOM), University of Catania, Italy.
Arturo Lo Giudice
https://orcid.org/0000-0003-1987-929X
Unit of Urology, Mediterranean Oncological Institute (IOM), University of Catania, Italy.
Maurizio Carrino
Unit of Urology, Cardarelli Hospital, Naples, Italy.
Salvatore Voce
Unit of Urology, Ravenna Hospital, Italy.
Andrea Cocci
Department of Urology, University of Florence, Italy.
Giulio Reale
Unit of Urology, Ravenna Hospital, Italy.
Andrea Minervini
Department of Urology, University of Florence, Italy.
Sebastiano Cimino
Department of Urology, University of Catania, Italy.
Giorgio Ivan Russo
Department of Urology, University of Catania, Italy.
Francesca Zingone
Unit of Urology, Mediterranean Oncological Institute (IOM), University of Catania, Italy.

Objective: The management of chronic prostatitis/chronic pelvic pain syndrome type III (CP/CPPS) has been always considered complex due to several biopsychological factors underlying the disease. In this clinical study, we aimed to evaluate the efficacy of the treatment with Palmitoylethanolamide, Epilobium and Calendula extract in patients with CP/CPPS III.
Materials and methods: From June 2023 to July 2023, we enrolled 45 consecutive patients affected by CP/CPPS type III in three different institution. We included patients aged between 18 and 75 years with symptoms of pelvic pain for 3 months or more before the study, a total National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score ≥ 12 point and diagnosed with NIH category III, according to 4-glass test Meares-Stamey test. Patients were then allocated to receive rectal suppositories of PEA, Epilobium and Calendula, 1 suppository/ die for 1 month. All patients have been tested with standard urinalysis in order to assess urinary leukocytes (U-WBC). The primary endpoint of the study was the reduction of NIHCPSI. The secondary outcomes were the change of peak flow, post-void residual (PVR), IIEF-5, VAS score, PSA and decrease of U-WBC.
Results: A total of 45 patients concluded the study protocol. At baseline, the median age of all the patients included in the cohort was 49 years, the median PSA was 2.81 ng/mL, the median NIH-CPSI was 18.55, the median IIEF-5 was 18.27, the median U-WBC was 485.3/mmc, the median VAS score was 6.49, the median PVR was 26.5 mL and the median peak flow was 16.3 mL/s. After 1 month of therapy we observed a statistically significant improvement of NIH-CPSI, U-WBC, PSA, IIEF-5, peak flow, PVR and VAS.
Conclusions: In this observational study, we showed the clinical efficacy of the treatment with PEA, Epilobium and Calendula, 1 suppository/die for 1 month, in patients with CP/CPPS III. The benefits of this treatment could be related to the reduction of inflammatory cells in the urine that could imply a reduction of inflammatory cytokines. These results should be confirmed in further studies with greater sample size.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Russo GI, Cimino S, Fragalà E, et al. Relationship between nonalcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. World J Urol. 2015; 33:743-51. DOI: https://doi.org/10.1007/s00345-014-1392-4
Morgia G, Mucciardi G, Galì A, et al. Treatment of chronic prostatitis/ chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int. 2010;84:400-6. DOI: https://doi.org/10.1159/000302716
Morgia G, Cimino S, Favilla V, et al. Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. International Braz J Urol. 2013; 39:214-21. DOI: https://doi.org/10.1590/S1677-5538.IBJU.2013.02.10
Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015; 116:509-25. DOI: https://doi.org/10.1111/bju.13101
Cocci A, Bocchino AC, Cito G, et al. Role of Rezum in the treatment of benign prostate hyperplasia: A review of the literature. Turk J Urol. 2021; 47:452-460. DOI: https://doi.org/10.5152/tud.2021.21128
Vanella L, Russo GI, Cimino S, et al. Correlation Between Lipid Profile and Heme Oxygenase System in Patients With Benign Prostatic Hyperplasia. Urology. 2014; 83:1444.e7-1444.e13. DOI: https://doi.org/10.1016/j.urology.2014.03.007
Morozov A, Bazarkin A, Babaevskaya D, et al. A systematic review and meta-analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2022; 82:633-56. DOI: https://doi.org/10.1002/pros.24311
Mykoniatis I, Pyrgidis N, Sokolakis I, et al. Low-intensity shockwave therapy for the management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis. BJU Int. 2021; 128:144-52. DOI: https://doi.org/10.1111/bju.15335
Pan J, Jin S, Xie Q, et al. Acupuncture for Chronic Prostatitis or Chronic Pelvic Pain Syndrome: An Updated Systematic Review and Meta-Analysis. Pain Res Manag. 2023; 2023:1-13. DOI: https://doi.org/10.1155/2023/7754876
Bozzini G, Provenzano M, Buffi N, et al. An observational study of the use of beclomethasone dipropionate suppositories in the treatment of lower urinary tract inflammation in men. BMC Urol. 2016; 16:25. DOI: https://doi.org/10.1186/s12894-016-0144-8
Morgia G, Russo GI, Urzì D, et al. A phase II, randomized, single- blinded, placebo-controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Arch Ital Urol Androl. 2017; 89:110. DOI: https://doi.org/10.4081/aiua.2017.2.110
Cicero AFG, Allkanjari O, Busetto GM, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. 2019; 91:139. DOI: https://doi.org/10.4081/aiua.2019.3.139
Deng L, Zong W, Tao X, et al. Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L. J Ethnopharmacol. 2019; 232:1-10.
Magistro G, Wagenlehner FME, Grabe M, et al. Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur Urol. 2016; 69:286-97. DOI: https://doi.org/10.1016/j.eururo.2015.08.061
Preethi KC, Kuttan G, Kuttan R. Anti-inflammatory activity of flower extract of Calendula officinalis Linn. and its possible mechanism of action. Indian J Exp Biol. 2009; 47:113-20.
Clayton P, Hill M, Bogoda N, et al. Palmitoylethanolamide: A Natural Compound for Health Management. Int J Mol Sci. 2021; 22:5305. DOI: https://doi.org/10.3390/ijms22105305
Deng L, Zong W, Tao X, et al. Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L. J Ethnopharmacol. 2019; 232:1-10. DOI: https://doi.org/10.1016/j.jep.2018.11.045

How to Cite

Morgia, G., Lo Giudice, A., Carrino, M., Voce, S., Cocci, A., Reale, G., Minervini, A., Cimino, S., Russo, G. I., & Zingone, F. (2024). Efficacy of palmitoylethanolamide, epilobium and calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Archivio Italiano Di Urologia E Andrologia, 96(2). https://doi.org/10.4081/aiua.2024.12582
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.